Evolus’ (EOLS) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Evolus (NASDAQ:EOLS) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a $22.00 target price on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Evolus in a report on Thursday, November 7th.

Evolus Stock Down 0.8 %

Shares of NASDAQ:EOLS opened at $14.02 on Tuesday. Evolus has a 1 year low of $9.25 and a 1 year high of $17.82. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The stock’s 50-day moving average is $11.75 and its 200 day moving average is $13.75. The company has a market cap of $887.75 million, a PE ratio of -15.41 and a beta of 1.32.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in EOLS. KBC Group NV purchased a new position in Evolus during the fourth quarter valued at $49,000. JPMorgan Chase & Co. lifted its position in Evolus by 63.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company’s stock valued at $2,753,000 after acquiring an additional 65,972 shares during the period. Lord Abbett & CO. LLC boosted its stake in Evolus by 23.4% during the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock worth $16,126,000 after acquiring an additional 188,685 shares in the last quarter. Barclays PLC grew its holdings in Evolus by 268.0% in the third quarter. Barclays PLC now owns 93,662 shares of the company’s stock worth $1,518,000 after purchasing an additional 68,213 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Evolus by 0.9% during the third quarter. Geode Capital Management LLC now owns 1,210,621 shares of the company’s stock valued at $19,616,000 after purchasing an additional 11,027 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.